OSLO, Norway, Nov. 1, 2018 /PRNewswire/ --
Targovax ASA (OSE: TRVX), a clinical stage biotechnology
company developing immune activators to target hard-to-treat solid
tumors, today announces its third quarter 2018 results.
Targovax's management will host an online presentation for
investors, analysts and the press at 08:45
CET. The presentation in Norwegian can be followed here, or
at: https://www.facebook.com/AXExposure/videos/279295392691286/
An English version can be found on Targovax Events &
Presentations from 08:45.
For a more elaborate presentation of Targovax, please visit
targovax.com for a replay of the 15 October
2018 Capital Markets Day.
HIGHLIGHTS FOR THE THIRD QUARTER 2018
- In July, Ludwig Cancer Research and the Cancer Research
Institute announced the completion of the safety evaluation for the
first dose cohort in the phase I/II trial of ONCOS-102 in
combination with MedImmune's checkpoint inhibitor (CPI) Imfinzi®
(durvalumab). The trial continued into the second dose cohort
- In July, Targovax and Sotio announced that the first patient
was dosed in the phase I/II combination trial in prostate cancer of
ONCOS-102 with DCVAC, a dendritic cell immune-therapy
- In September, Targovax announced interim response rate and
immune activation results for the first six patients in the phase I
combination trial of ONCOS-102 and Keytruda® in checkpoint
inhibitor refractory melanoma, including one patient with a
complete response
- In September, Targovax announced publication of new ONCOS-102
in vivo data in the Journal of Medical Virology, showing T-cell
activation in a mesothelioma model
- In September, Targovax announced the appointment of Torbjørn
Furuseth as Chief Financial Officer, with Erik Digman Wiklund transitioning to the role of
Chief Business Officer
POST-PERIOD HIGHLIGHTS
- In October, the Company reported the full data set from the
TG01 trial in resected pancreatic cancer, including encouraging
disease-free survival data
- In October, the Company hosted a Key Opinion Leader Symposium
on oncolytic viruses in New York
City, with speakers from Memorial Sloan Kettering Cancer
Centre
- In October, the Company hosted a Capital Markets Day in
Oslo, Norway, and provided an
update on the TG program development strategy
Øystein Soug, CEO commented: "Targovax has made great
progress in 2018. We have four ongoing clinical trials with our
lead clinical product, ONCOS-102, and we reported interim response
rate and immune activation data from the trials in mesothelioma and
checkpoint inhibitor refractory melanoma. In particular, it was
encouraging to see a complete response so early in the melanoma
trial, which makes us confident that ONCOS-102 has the potential to
provide an important future benefit for difficult-to-treat CPI
refractory patients. We are now planning to expand the dosing to
fully unlock that potential.
The results from the TG01 trial in resected pancreatic cancer
have now also been fully analyzed. We see a very encouraging signal
of efficacy, compared to historical control, both in terms of
disease-free survival and overall survival. Whilst the ONCOS
oncolytic virus program will remain our priority, we plan to
continue and expand the TG development program. Based on the TG01
data, several academic groups have expressed interest in sponsoring
pancreatic cancer combination trials with the TG vaccine. In
addition, we will seek to combine TG vaccination with a checkpoint
inhibitor in a small proof-of-concept trial."
Reporting material
Targovax third quarter 2018 report
Targovax third quarter 2018 presentation
The quarterly report and presentation are also available at the
website www.targovax.com.
For further information, please contact:
Renate Birkeli, Investor
Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com
Media and IR enquires:
Andreas Tinglum - Corporate
Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no
Simon Conway/Stephanie Cuthbert - FTI Consulting
(International)
Phone: +44-20-3727-1000
Email: Targovax@fticonsulting.com
About Targovax
Activating the patient's immune system to fight
cancer
Targovax (OSE:TRVX) is a clinical stage biotechnology company
developing immune activators to target hard-to-treat solid tumors.
Immuno-oncology is currently one of the fastest growing therapeutic
fields in medicine.
Targovax's lead product candidate, ONCOS-102, is a genetically
modified oncolytic adenovirus, which has been engineered to
selectively infect and replicate in cancer cells. It has been shown
to activate the immune system to generate tumor-specific immune
responses. In phase I trials, ONCOS-102 induced both local and
systemic innate and adaptive immune activation, which has been
associated with clinical benefit. ONCOS-102's lead indication is
mesothelioma, where the virus is currently being tested in a
randomized phase II trial, with a phase Ib safety lead-in cohort.
Another trial, in advanced melanoma, is expected to produce
important proof of concept data for checkpoint inhibitor refractory
patients.
Targovax is also developing a neo-antigen cancer vaccine
targeting tumors that express mutated forms of RAS - mutations
known to drive cancer. The TG vaccine program has shown a signal of
efficacy compared to historical control in a 32-patient trial with
TG01 in resected pancreatic cancer. A next generation product
candidate, TG02 is currently tested as monotherapy and will also be
tested in combination with KEYTRUDA® (an anti-PD1 check point
inhibitor, CPI).
This information was brought to you by
Cision http://news.cision.com
http://news.cision.com/targovax/r/targovax-asa--third-quarter-2018-results,c2661643
The following files are available for download:
Q3 report -
http://mb.cision.com/Public/17093/2661643/85f997ca69858bc3.pdf
Presentation -
http://mb.cision.com/Public/17093/2661643/85bb7888f3ba0149.pdf
View original
content:http://www.prnewswire.com/news-releases/targovax-asa-third-quarter-2018-results-300742017.html
SOURCE Targovax